^
    Back
    Association details:
    Biomarker:EGFR overexpression
    Cancer:Colorectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Sci Transl Med
    Title:

    IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies

    Excerpt:
    Five of 21 SD models (23.8%) characterized by particularly high expression of EGFR and EGFR family members regressed after intensified EGFR blockade by cetuximab and a small-molecule inhibitor....interception of IGF2-dependent signaling in IGF2-overexpressing xenopatients potentiated the effects of cetuximab.
    DOI:
    10.1126/scitranslmed.3010445
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Ann Surg
    Title:

    Activating KRAS Mutations and Overexpression of Epidermal Growth Factor Receptor as Independent Predictors in Metastatic Colorectal Cancer Patients Treated With Cetuximab

    Excerpt:
    Patients with tumors that express high EGFR levels or harbor wild-type KRAS are more likely to have a better PFS and OS when treated with cetuximab plus chemotherapy (all P < 0.05).
    Secondary therapy:
    Chemotherapy
    DOI:
    10.1097/SLA.0b013e3181bc9d96